--CSO Kevin Foley to highlight FDA IND clearance for Ranok�s first clinical program, RNK05047, that was developed using the company�s innovative CHAMP� technology platform
BOSTON & HANGZHOU, China--(BUSINESS WIRE)--Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer and other serious diseases, today announced that Kevin P. Foley, Ph.D., Co-founder and Chief Scientific Officer of Ranok, will present at the virtual BMO BioPharma Spotlight Series: Proteins � Degraders and Other Next Gen Technologies on Thursday, February 24th at 10:10 AM ET.
Dr. Foley will review the company�s strategic vision and its first clinical program, RNK05047, a first-in-class, small-molecule, BRD4-selective protein degrader which was discovered and developed using Ranok�s proprietary approach to targeted protein degradation, CHAMP� (Chaperone-mediated Protein Degradation). This technology leverages the company�s expertise in protein homeostasis and the cellular chaperone network to degrade disease-associated proteins, and is designed to increase drug safety and efficacy through selective targeting of disease tissues. The U.S. Food and Drug Administration (FDA) has cleared the company�s investigational new drug application (IND) for RNK05047 and enrollment of the Phase 1/2 study for patients with advanced solid tumors and lymphomas is expected to begin in the first half of 2022.
Following the presentation, a recording will be available for 3 months on Ranok�s website at: https://ranoktherapeutics.com/events.html
About Ranok Therapeutics
Ranok is a privately held biopharmaceutical company that is pioneering CHAMP�, an innovative approach to targeted protein degradation for the discovery and development of novel therapeutics. Our R&D team brings deep biological insight and chemistry expertise to rapidly identify and advance CHAMP� degraders for a variety of important disease targets, with the goal to create transformative medicines that benefit patients around the world suffering from cancer and other serious diseases. For more information, please visit the company website at www.ranoktherapeutics.com or follow us on Twitter (@RanokTx) and LinkedIn.
About Ranok�s CHAMP� platform
Ranok�s proprietary Chaperone-mediated Protein Degradation/Degrader (CHAMP�) platform and Chaperone-Tether Library� are based on our founders� extensive backgrounds researching protein homeostasis. CHAMP� technology takes advantage of the cellular chaperone network, which regulates the folding and stability of proteins, distinguishing it from other targeted protein degradation approaches. CHAMP� has a number of unique advantages, such as the evasion of mechanisms of drug resistance, and is designed to improved safety and efficacy due to the selective targeting of disease tissues.
About RNK05047
RNK05047 is a first-in-class, small-molecule, BRD4-selective protein degrader that was discovered and developed using Ranok�s proprietary approach to targeted protein degradation, CHAMP�. The bromodomain transcription factor BRD4 is a master regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. The U.S. Food and Drug Administration (FDA) has cleared the company�s investigational new drug application (IND) for RNK05047 and Ranok expects to begin enrollment of the Phase 1/2 study entitled CHAMP-1 in the first half of 2022 for patients with advanced solid tumors and lymphomas.
Contacts
US Media & Investors:
Ms. Beth Kurth
Conway Communications
[email protected]
China Media & Investors:
Mr. Lei Zhang
Ranok Therapeutics
[email protected]
